Goldman Sachs Group Inc Prometheus Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 14, 2024
SELL
$103.46 - $126.29 $17 Million - $20.7 Million
-164,266 Reduced 44.5%
204,858 $22 Million
Q1 2023

May 11, 2023
SELL
$103.46 - $126.29 $17 Million - $20.7 Million
-164,266 Reduced 44.5%
204,858 $22 Million
Q4 2022

May 14, 2024
BUY
$36.06 - $117.21 $4.58 Million - $14.9 Million
127,134 Added 52.54%
369,124 $40.6 Million
Q4 2022

Feb 13, 2023
BUY
$36.06 - $117.21 $4.58 Million - $14.9 Million
127,134 Added 52.54%
369,124 $40.6 Million
Q3 2022

May 14, 2024
BUY
$28.17 - $59.01 $832,479 - $1.74 Million
29,552 Added 13.91%
241,990 $14.3 Million
Q3 2022

Nov 10, 2022
BUY
$28.17 - $59.01 $832,479 - $1.74 Million
29,552 Added 13.91%
241,990 $14.3 Million
Q2 2022

May 14, 2024
BUY
$22.39 - $38.94 $4.76 Million - $8.27 Million
212,438 New
212,438 $6 Million
Q2 2022

Aug 15, 2022
SELL
$22.39 - $38.94 $1.91 Million - $3.32 Million
-85,290 Reduced 28.65%
212,438 $6 Million
Q1 2022

May 16, 2022
BUY
$30.13 - $50.0 $7.82 Million - $13 Million
259,436 Added 677.52%
297,728 $11.2 Million
Q4 2021

Feb 14, 2022
SELL
$22.28 - $39.54 $2.93 Million - $5.2 Million
-131,442 Reduced 77.44%
38,292 $1.51 Million
Q3 2021

Nov 10, 2021
BUY
$20.89 - $26.96 $3.55 Million - $4.58 Million
169,734 New
169,734 $4.02 Million

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email